Literature DB >> 8684608

Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases.

J B Schulz1, R T Matthews, D R Henshaw, M F Beal.   

Abstract

Neuronal death in neurodegenerative diseases may involve energy impairment leading to secondary excitotoxicity, and free radical generation. Potential therapies for the treatment of neurodegenerative diseases therefore include glutamate release blockers, excitatory amino acid receptor antagonists, agents that improve mitochondrial function, and free radical scavengers. In the present study we examined whether these strategies either alone or in combination had neuroprotective effects against striatal lesions produced by mitochondrial toxins. The glutamate release blockers lamotrigine and BW1003C87 significantly attenuated lesions produced by intrastriatal administration of 1-methyl-4-phenylpyridinium. Lamotrigine significantly attenuated lesions produced by systemic administration of 3-nitropropionic acid. Memantine, an N-methyl-D-aspartate antagonist, protected against malonate induced striatal lesions. We previously found that coenzyme Q10 and nicotinamide, and the free radical spin trap n-tert-butyl-alpha-(2-sulfophenyl)-nitrone (S-PBN) dose-dependently protect against lesions produced by intrastriatal injection of malonate. In the present study we found that the combination of MK-801 (dizocipiline) with coenzyme Q10 exerted additive neuroprotective effects against malonate. Lamotrigine with coenzyme Q10 was more effective than coenzyme Q10 alone. The combination of nicotinamide with S-PBN was more effective than nicotinamide alone. These results provide further evidence that glutamate release inhibitors and N-acetyl-D-aspartate antagonists can protect against secondary excitotoxic lesions in vivo. Furthermore, they show that combinations of agents which act at sequential steps in the neurodegenerative process can produce additive neuroprotective effects. These findings suggest that combinations of therapies to improve mitochondrial function, to block excitotoxicity and to scavenge free radicals may be useful in treating neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8684608     DOI: 10.1016/0306-4522(95)00527-7

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  25 in total

1.  Neuroprotective potential of ionotropic glutamate receptor antagonists.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

2.  Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain.

Authors:  Gislaine Z Réus; Roberto B Stringari; Gislaine T Rezin; Daiane B Fraga; Juliana F Daufenbach; Giselli Scaini; Joana Benedet; Natália Rochi; Emílio L Streck; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2011-09-28       Impact factor: 3.575

Review 3.  Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Authors:  Wojciech Danysz; Chris G Parsons
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo.

Authors:  D Pubill; E Verdaguer; A M Canudas; F X Sureda; E Escubedo; J Camarasa; M Pallàs; A Camins
Journal:  Br J Pharmacol       Date:  2001-02       Impact factor: 8.739

5.  Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

Authors:  Robert J Ferrante; Ole A Andreassen; Alpaslan Dedeoglu; Kimberly L Ferrante; Bruce G Jenkins; Steven M Hersch; M Flint Beal
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

6.  In vitro neuroprotection against oxidative stress by pre-treatment with a combination of dihydrolipoic acid and phenyl-butyl nitrones.

Authors:  Michael L Koenig; James L Meyerhoff
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

7.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

8.  Catecholamine neuron groups in rat brain slices differ in their susceptibility to excitatory amino acid induced dendritic degeneration.

Authors:  P T Bywood; S M Johnson
Journal:  Neurotox Res       Date:  2001-11       Impact factor: 3.911

9.  Spotlight on lamotrigine in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.